Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
ALXN

Alexion

$129.73

0.83 (0.64%)

, AMGN

Amgen

$186.84

-0.13 (-0.07%)

08:01
02/21/19
02/21
08:01
02/21/19
08:01
Conference/Events
The ASBMT and CIBMTR to hold a meeting »

The Center for…

ALXN

Alexion

$129.73

0.83 (0.64%)

AMGN

Amgen

$186.84

-0.13 (-0.07%)

ATNM

Actinium Pharmaceuticals

$0.66

0.0961 (17.16%)

AXN

Aoxing Pharmaceutical

$0.00

(0.00%)

BLUE

Bluebird Bio

$133.31

-2.56 (-1.88%)

CELG

Celgene

$90.39

-0.32 (-0.35%)

ORTX

Orchard Therapeutics

$16.00

-0.25 (-1.54%)

OMER

Omeros

$14.67

0.79 (5.69%)

NVS

Novartis

$90.77

0.82 (0.91%)

MRK

Merck

$79.44

0.18 (0.23%)

STML

Stemline

$11.71

0.16 (1.39%)

SPPI

Spectrum

$11.61

-0.1 (-0.85%)

JAZZ

Jazz Pharmaceuticals

$126.72

-0.28 (-0.22%)

INCY

Incyte

$83.74

-0.33 (-0.39%)

SNY

Sanofi

$42.07

-0.14 (-0.33%)

SHPG

Shire

$0.00

(0.00%)

HSGX

Histogenics

$0.13

0.0046 (3.56%)

GLYC

GlycoMimetics

$11.85

0.24 (2.07%)

SGEN

Seattle Genetics

$69.78

-0.22 (-0.31%)

PFE

Pfizer

$42.21

-0.37 (-0.87%)

GILD

Gilead

$66.98

0.22 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 24

    May

  • 28

    May

  • 17

    Jun

Over a week ago
INCY

Incyte

$83.45

2.49 (3.08%)

08:22
02/15/19
02/15
08:22
02/15/19
08:22
Recommendations
Incyte analyst commentary at RBC Capital »

Incyte price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

INCY

Incyte

$37.00

14 (5.00%)

16:39
02/14/19
02/14
16:39
02/14/19
16:39
Syndicate
Breaking Syndicate news story on Incyte »

Incyte files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 24

    May

INCY

Incyte

$83.75

2.79 (3.45%)

12:51
02/14/19
02/14
12:51
02/14/19
12:51
Recommendations
Incyte analyst commentary at Piper Jaffray »

Incyte guidance appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 24

    May

INCY

Incyte

$80.96

-0.43 (-0.53%)

07:15
02/14/19
02/14
07:15
02/14/19
07:15
Earnings
Incyte sees FY19 Jakafi net product revenues $1.58B-$1.65B »

Sees GAAP and Non-GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 24

    May

INCY

Incyte

$80.96

-0.43 (-0.53%)

07:14
02/14/19
02/14
07:14
02/14/19
07:14
Earnings
Incyte reports Q4 EPS 32c, consensus 46c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 24

    May

INCY

Incyte

$81.41

0.05 (0.06%)

07:21
02/07/19
02/07
07:21
02/07/19
07:21
Hot Stocks
Incyte says FDA extended review period for ruxolitinib »

Incyte announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 24

    May

INCY

Incyte

$81.58

-1.33 (-1.60%)

08:51
02/05/19
02/05
08:51
02/05/19
08:51
Recommendations
Incyte analyst commentary at SunTrust »

Incyte price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 24

    May

LLY

Eli Lilly

$120.15

-0.7 (-0.58%)

, INCY

Incyte

$81.58

-1.33 (-1.60%)

19:28
02/04/19
02/04
19:28
02/04/19
19:28
Hot Stocks
Lilly, Incyte say baricitinib met primary endpoint on BREEZE-AD trials »

Eli Lilly and Company…

LLY

Eli Lilly

$120.15

-0.7 (-0.58%)

INCY

Incyte

$81.58

-1.33 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

  • 18

    May

  • 24

    May

AMAT

Applied Materials

$39.18

1.37 (3.62%)

, MRK

Merck

$72.94

-0.25 (-0.34%)

12:23
01/26/19
01/26
12:23
01/26/19
12:23
Periodicals
Micron, Merck facilities have great exposure to climate change, Barron's says »

Extreme weather affects…

AMAT

Applied Materials

$39.18

1.37 (3.62%)

MRK

Merck

$72.94

-0.25 (-0.34%)

STX

Seagate

$43.67

2.68 (6.54%)

EMN

Eastman Chemical

$80.87

2.795 (3.58%)

MU

Micron

$38.97

2.37 (6.48%)

NEE

NextEra Energy

$174.23

-6.15 (-3.41%)

WDC

Western Digital

$43.19

3.06 (7.63%)

NCLH

Norwegian Cruise Line

$47.93

0.95 (2.02%)

PEG

PSEG

$52.64

-0.61 (-1.15%)

D

Dominion

$69.13

0.05 (0.07%)

RCL

Royal Caribbean

$111.76

2.05 (1.87%)

INCY

Incyte

$79.91

2.87 (3.73%)

TROW

T. Rowe Price

$94.47

0.61 (0.65%)

BMY

Bristol-Myers

$48.94

-0.09 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 04

    Feb

  • 10

    Feb

  • 14

    Feb

  • 14

    Feb

  • 16

    Feb

  • 25

    Feb

  • 28

    Feb

  • 04

    Mar

  • 25

    Mar

  • 26

    Mar

  • 11

    Apr

  • 18

    May

  • 20

    May

  • 24

    May

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.